Screener
Agios Pharmaceuticals AGIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's EPS (diluted)?
- Agios Pharmaceuticals (AGIO) reported EPS (diluted) of -$1.69 in Q2 2026.
- How has Agios Pharmaceuticals's EPS (diluted) changed year-over-year?
- Agios Pharmaceuticals's EPS (diluted) increased by 12.4% year-over-year, from -$1.93 to -$1.69.
- What is the long-term trend for Agios Pharmaceuticals's EPS (diluted)?
- Over 2 years (2021 to 2025), Agios Pharmaceuticals's EPS (diluted) has grown at a -43.5% compound annual growth rate (CAGR), from $22.24 to -$7.11.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Agios Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude